'Incorrect and misleading' data prompted regulators' decision to pull Tavneos from Europe

Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision

With the European Union formally reversing its marketing authorization for rare disease med Tavneos last week, regulators from the bloc are laying out their concerns on the data backing the complem | With the European…